AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

12.68 +0.31 (+2.51%)

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

April 20, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

April 01, 2026

From AbCellera Biologics Inc.

Via Business Wire

CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It ↗

March 26, 2026

The CRA confirmed $7,000 in TFSA room for 2026. Here's why AbCellera Biologics could be one of the smartest growth stocks to put that money to work in right now.

Via The Motley Fool

AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall ↗

February 24, 2026

Via Chartmill

Topics Intellectual Property

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

February 24, 2026

Via Chartmill

AbCellera Reports Full Year 2025 Business Results

February 24, 2026

From AbCellera Biologics Inc.

Via Business Wire

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

February 11, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

January 22, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

January 12, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera and Bruker Reach Global Settlement of Patent Litigation

December 18, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

November 10, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗

November 06, 2025

AbCellera's Q3 2025 results show revenue beat estimates, but the net loss widened, causing a negative after-hours stock reaction.

Via Chartmill

AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗

November 07, 2025

Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technology stocks toward their worst week since April.

Via Benzinga

Topics Artificial Intelligence

AbCellera Reports Q3 2025 Business Results

November 06, 2025

From AbCellera Biologics Inc.

Via Business Wire

AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗

November 06, 2025

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto...

Via Benzinga

Topics Artificial Intelligence

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

October 07, 2025

From AbCellera Biologics Inc.

Via Business Wire

Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus ↗

October 02, 2025

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.

Via Benzinga

Topics Stocks

Why Did AbCellera's Stock Jump Over 7% After Hours? ↗

October 02, 2025

AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performance expected in Q3 earnings.

Via Benzinga

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

September 29, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

September 10, 2025

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

August 27, 2025

From AbCellera Biologics Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 18, 2025

Via Benzinga

AbCellera to Participate at Upcoming Investor Conferences in September

August 12, 2025

From AbCellera Biologics Inc.

Via Business Wire

Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts ↗

August 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 08, 2025

Via Benzinga

AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript ↗

August 08, 2025

Via The Motley Fool

Topics Earnings

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

August 07, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

August 07, 2025

From AbCellera Biologics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.